Apellis Pharmaceuticals (NASDAQ: APLS) (FRA: 1JK) stock is down 37%. That APLS stock fall has wiped out near $4 billion in market capitalisation - or, to put that the other way, destroyed near $4 billion of stockholder wealth. A useful instance and lesson to us of the fragility inherent in investing in pharma stocks. While approval, FDA authorisation, can produce excellent increases in value that's not the end of the story by any means. There can still be disasters after that.
As to what is done at Apellis: “Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.” Well, OK. but the thing that has really been driving the recent valuation is an eye treatment: “APLS stock uptick in the last six months can be significantly attributed to the FDA's approval of Syfovre (pegcetacoplan injection) to treat geographic atrophy (GA) secondary to age-related macular degeneration. The drug is the first and only approved therapy for GA.” Which is great, obviously, all that hard work paid off, there's a drug out there on the market and revenue can be gained.

Apellis Pharmaceuticals stock price from NASDAQ
Unfortunately it's precisely and exactly that eye drug which is causing the problem right now. “Six recipients of Apellis Pharmaceuticals' (APLS) new eye-disease drug, Syfovre, experienced inflammation in their eyes, according to a report that sent APLS stock crashing Monday.” At which point we might wonder what all the fuss is about. They've shipped 60,000 vials so far, a 0.001% infection rate is actually pretty good. We might think.
But the problem is that no one, at this stage, knows why. So, is it a manufacturing problem? An infection getting into the vial at the factory end? That would be surprising, to say the least, also very expensive indeed for Apellis. It's also possible to muse, as some are, that as a very viscous fluid injected with the doctor's own (rather than newly supplied) syringe, perhaps it's more of a physical effect of the treatment application? Or, finally, there's the point that the operation of the drug is to, locally, suppress the immune system, so perhaps it's just one of those things? The benefits greater than these rare costs and that's just the way it is?
The answer does matter - one of those answers allows sales to continue. So there's going to be considerable uncertainty about the Apellis stock price until we know the answer to why the infections. A mistake somewhere along the line? Or just a side effect that has to be put up with for the benefits gained to 99.9% of the patients?